JP2015508054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508054A5 JP2015508054A5 JP2014553633A JP2014553633A JP2015508054A5 JP 2015508054 A5 JP2015508054 A5 JP 2015508054A5 JP 2014553633 A JP2014553633 A JP 2014553633A JP 2014553633 A JP2014553633 A JP 2014553633A JP 2015508054 A5 JP2015508054 A5 JP 2015508054A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- inhibitor
- factor
- combination
- direct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 14
- 210000000130 stem cell Anatomy 0.000 claims 8
- 229940123688 Direct Factor Xa inhibitor Drugs 0.000 claims 7
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 7
- 210000004185 liver Anatomy 0.000 claims 6
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003868 thrombin inhibitor Substances 0.000 claims 5
- 229940122093 Indirect Factor Xa inhibitor Drugs 0.000 claims 4
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- 239000004019 antithrombin Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 108010055460 bivalirudin Proteins 0.000 claims 3
- 229960001500 bivalirudin Drugs 0.000 claims 3
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- -1 retaxane Chemical compound 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 108010007267 Hirudins Proteins 0.000 claims 2
- 102000007625 Hirudins Human genes 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000018317 Keratin-19 Human genes 0.000 claims 2
- 108010066302 Keratin-19 Proteins 0.000 claims 2
- 108010000499 Thromboplastin Proteins 0.000 claims 2
- 102000002262 Thromboplastin Human genes 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 210000003494 hepatocyte Anatomy 0.000 claims 2
- 229940006607 hirudin Drugs 0.000 claims 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000005229 liver cell Anatomy 0.000 claims 2
- 210000005009 osteogenic cell Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002947 procoagulating effect Effects 0.000 claims 2
- 229960001148 rivaroxaban Drugs 0.000 claims 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- NOBZETMXGVAWIM-UHFFFAOYSA-N 4-[(2-carbamimidoyl-3,4-dihydro-1h-isoquinolin-7-yl)oxymethyl]-1-pyridin-4-ylpiperidine-4-carboxylic acid;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=C2CN(C(=N)N)CCC2=CC=C1OCC(CC1)(C(O)=O)CCN1C1=CC=NC=C1 NOBZETMXGVAWIM-UHFFFAOYSA-N 0.000 claims 1
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 101710163968 Antistasin Proteins 0.000 claims 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 229960003886 apixaban Drugs 0.000 claims 1
- 229960003856 argatroban Drugs 0.000 claims 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims 1
- 229950011103 betrixaban Drugs 0.000 claims 1
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 229960003850 dabigatran Drugs 0.000 claims 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims 1
- IJNIQYINMSGIPS-UHFFFAOYSA-N darexaban Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC(O)=C1NC(=O)C1=CC=C(N2CCN(C)CCC2)C=C1 IJNIQYINMSGIPS-UHFFFAOYSA-N 0.000 claims 1
- 229950004553 darexaban Drugs 0.000 claims 1
- 229940019332 direct factor xa inhibitors Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960000622 edoxaban Drugs 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims 1
- 229960002137 melagatran Drugs 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims 1
- 229960001522 ximelagatran Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/051157 WO2012101181A1 (en) | 2011-01-25 | 2012-01-25 | Compositions and methods for cell transplantation |
| EPPCT/EP2012/051157 | 2012-01-25 | ||
| PCT/EP2012/061534 WO2013110354A1 (en) | 2012-01-25 | 2012-06-15 | Compositions and methods for cell transplantation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508054A JP2015508054A (ja) | 2015-03-16 |
| JP2015508054A5 true JP2015508054A5 (cg-RX-API-DMAC7.html) | 2015-07-02 |
| JP6034406B2 JP6034406B2 (ja) | 2016-11-30 |
Family
ID=46507976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553633A Expired - Fee Related JP6034406B2 (ja) | 2012-01-25 | 2012-06-15 | 細胞移植のための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9775890B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2806879B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6034406B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2726802T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013110354A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2667878B1 (en) | 2011-01-25 | 2016-03-30 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| CN104038425B (zh) * | 2013-03-06 | 2018-01-02 | 阿里巴巴集团控股有限公司 | 转发以太网报文的方法和装置 |
| US20160129047A1 (en) | 2013-07-05 | 2016-05-12 | Université Catholique de Louvain | Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders |
| EP2843416A1 (de) * | 2013-09-02 | 2015-03-04 | Siemens Healthcare Diagnostics Products GmbH | Kontroll- und Kalibratormaterial für die Bestimmung von direkten Antikoagulanzien |
| MA45274A (fr) * | 2016-03-02 | 2019-01-09 | Univ Catholique Louvain | Préparations améliorées de cellules progénitrices hépatiques adultes |
| CN116590227A (zh) * | 2017-03-03 | 2023-08-15 | 日本乐敦制药株式会社 | 间充质干细胞和肝疾病治疗剂 |
| US10567300B2 (en) | 2017-11-22 | 2020-02-18 | Cisco Technology, Inc. | Layer 3 fair rate congestion control notification |
| US10785161B2 (en) | 2018-07-10 | 2020-09-22 | Cisco Technology, Inc. | Automatic rate limiting based on explicit network congestion notification in smart network interface card |
| CN113677790B (zh) * | 2019-03-26 | 2024-05-24 | 普罗米瑟拉疗法公司 | 用于治疗慢加急性肝衰竭的成体肝祖细胞 |
| US10986026B2 (en) | 2019-06-11 | 2021-04-20 | Cisco Technology, Inc. | Proportional integral based shaper for lossless output buffer |
| CN116157164A (zh) * | 2020-05-26 | 2023-05-23 | 万能医药公司 | 抗凝剂化合物及其使用方法和装置 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010552D0 (en) | 1990-05-10 | 1990-07-04 | Erba Carlo Spa | Method for the recombinant production of hirudins and novel hirudins |
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| US5837539A (en) | 1990-11-16 | 1998-11-17 | Osiris Therapeutics, Inc. | Monoclonal antibodies for human mesenchymal stem cells |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| US5827740A (en) | 1996-07-30 | 1998-10-27 | Osiris Therapeutics, Inc. | Adipogenic differentiation of human mesenchymal stem cells |
| DE10041402A1 (de) | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| GB0014136D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| DE10202982A1 (de) | 2002-01-26 | 2003-07-31 | Augustinus Bader | Verfahren und Vorrichtung zum Einbringen von lebenden Zellen in eine biologische Körperflüssigkeit |
| US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
| WO2006126219A1 (en) | 2005-05-26 | 2006-11-30 | Fresenius Medical Care Deutschland G.M.B.H. | Liver progenitor cells |
| AU2006292203A1 (en) | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| CA2634510C (en) * | 2005-12-21 | 2018-01-09 | Universite Catholique De Louvain | Isolated liver stem cells |
| EP2667878B1 (en) | 2011-01-25 | 2016-03-30 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
-
2012
- 2012-06-15 WO PCT/EP2012/061534 patent/WO2013110354A1/en not_active Ceased
- 2012-06-15 JP JP2014553633A patent/JP6034406B2/ja not_active Expired - Fee Related
- 2012-06-15 EP EP12734831.6A patent/EP2806879B1/en active Active
- 2012-06-15 ES ES12734831T patent/ES2726802T3/es active Active
- 2012-06-15 US US14/374,730 patent/US9775890B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508054A5 (cg-RX-API-DMAC7.html) | ||
| JP2014508138A5 (cg-RX-API-DMAC7.html) | ||
| van Ryn et al. | The discovery of dabigatran etexilate | |
| MX2019008252A (es) | Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso. | |
| CO6341565A2 (es) | Inhibidores macrociclicos de serina proteasas de hepatitis c | |
| AR082444A1 (es) | Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| CL2011003276A1 (es) | Compuesto amida del ácido {5-[4-{3,3-dimetll-azetidina-1-carbonil)-fenil]-[l,2,4]trlaz010[l,5-a]piridin-2-1i} clclopropanocarboxillco; inhibldor de jak1: composición farmacéutica que lo comprende: uso del compuesto en la profilaxis ylo tratamiento de afecciones inflamatorias, autolnmunltarias, proliferativas, entre otras. | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| Kim et al. | The therapeutic effects of optimal dose of mesenchymal stem cells in a murine model of an elastase induced-emphysema | |
| PE20141318A1 (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando acidos organicos | |
| MX375836B (es) | Composiciones y métodos para inhibir la expresión del gen de alfa-1 antitripsina. | |
| Ma et al. | Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K | |
| IN2014MN01892A (cg-RX-API-DMAC7.html) | ||
| HK1249433A1 (zh) | 含有mk2抑制剂肽的组合物用於治疗非小细胞肺癌的用途 | |
| Li et al. | HMGB1 affects the development of pulmonary arterial hypertension via RAGE. | |
| IL292655A (en) | Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies | |
| AR038141A1 (es) | Composiciones farmaceuticas estables que comprenden inhibidor(es) de ace | |
| Fu | Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance | |
| Chen et al. | Exosomes derived from human umbilical cord mesenchymal stem cells protect against papain-induced emphysema by preventing apoptosis through activating VEGF-VEGFR2-mediated AKT and MEK/ERK pathways in rats | |
| van Iersel et al. | Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue | |
| RU2012122793A (ru) | Композиция, способ и набор для альфа-1 ингибитора протеазы | |
| IN2014DN05784A (cg-RX-API-DMAC7.html) | ||
| MX2012009976A (es) | Uretanos, ureas, amidinas e inhibidores relacionados del factor xa. | |
| Kupatt et al. | Embryonic endothelial progenitor cell-mediated cardioprotection requires Thymosin β4 |